Literature DB >> 18817505

Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points.

Kerri A Thom1, Michelle D Shardell, Regina B Osih, Marin L Schweizer, Jon P Furuno, Eli N Perencevich, Jessina C McGregor, Anthony D Harris.   

Abstract

BACKGROUND: Severity of illness is an important confounder in outcome studies involving infectious diseases. However, it is unclear whether the time at which severity of illness is measured is important.
METHODS: We performed a retrospective study of 328 episodes of gram-negative bacteremia in adult patients to assess the impact of the time of measurement of severity of illness on the association between empirical antimicrobial therapy received and in-hospital mortality. Using a modified Acute Physiology Score (APS), severity of illness was measured at 2 time points: (1) hospital admission and (2) 24 hours before the first culture-positive blood sample was collected. Multivariate logistic regression was used to estimate the impact of adjusting for the APS on the relationship between empirical therapy received (ie, the exposure) and in-hospital mortality (ie, the outcome).
RESULTS: The mean APS (+/- standard deviation) of patients with bacteremia increased during their hospital stay (from 19.2 +/- 11.6 at admission to 24.2 +/- 13.6 at the second time point; P < .01). When examining the association between empirical antimicrobial therapy received and in-hospital mortality, and controlling for the APS, there was a trend toward a decreased impact of appropriate therapy received on in-hospital mortality. The unadjusted odds ratio (OR) for the association between appropriate therapy received and in-hospital mortality was 0.83 (95% confidence interval [CI], 0.51-1.34). After controlling for the APS at admission, this association was attenuated (OR, 0.94 [95% CI, 0.57-1.55]), and when a change in the APS was also included in the multivariate logistic regression model, the association was further attenuated (OR, 0.99 [95% CI, 0.58-1.69]).
CONCLUSIONS: The magnitude of the association between appropriate antimicrobial therapy received and in-hospital mortality among patients with gram-negative bacteremia was sensitive to the timing of adjustment for severity of illness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18817505      PMCID: PMC2716043          DOI: 10.1086/591453

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  18 in total

1.  Excess shock and mortality in Staphylococcus aureus related to methicillin resistance.

Authors:  E N Perencevich
Journal:  Clin Infect Dis       Date:  2000-11       Impact factor: 9.079

2.  Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.

Authors:  F Vidal; J Mensa; M Almela; J A Martínez; F Marco; C Casals; J M Gatell; E Soriano; M T Jimenez de Anta
Journal:  Arch Intern Med       Date:  1996-10-14

3.  Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control.

Authors:  D S Hansen; A Gottschau; H J Kolmos
Journal:  J Hosp Infect       Date:  1998-02       Impact factor: 3.926

4.  Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.

Authors:  Stephan Harbarth; Jorge Garbino; Jérome Pugin; Jacques A Romand; Daniel Lew; Didier Pittet
Journal:  Am J Med       Date:  2003-11       Impact factor: 4.965

5.  Klebsiella bacteremia: a review of 196 episodes during a decade (1980-1989).

Authors:  C Watanakunakorn; J Jura
Journal:  Scand J Infect Dis       Date:  1991

6.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults.

Authors:  W A Knaus; D P Wagner; E A Draper; J E Zimmerman; M Bergner; P G Bastos; C A Sirio; D J Murphy; T Lotring; A Damiano
Journal:  Chest       Date:  1991-12       Impact factor: 9.410

7.  Bacteraemia due to Escherichia coli in a Danish university hospital, 1986-1990.

Authors:  B Olesen; H J Kolmos; F Orskov; I Orskov; A Gottschau
Journal:  Scand J Infect Dis       Date:  1995

8.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

Review 9.  Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy.

Authors:  C S Bryan; K L Reynolds; E R Brenner
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

10.  Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence.

Authors:  Alexandre R Marra; Sérgio B Wey; Adauto Castelo; Ana Cristina Gales; Ruy Guilherme R Cal; José R do Carmo Filho; Michael B Edmond; Carlos Alberto P Pereira
Journal:  BMC Infect Dis       Date:  2006-02-14       Impact factor: 3.090

View more
  19 in total

Review 1.  Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.

Authors:  Mical Paul; Vered Shani; Eli Muchtar; Galia Kariv; Eyal Robenshtok; Leonard Leibovici
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

2.  Tree-Based Models for Predicting Mortality in Gram-Negative Bacteremia: Avoid Putting the CART before the Horse.

Authors:  Nathaniel J Rhodes; J Nicholas O'Donnell; Bryan D Lizza; Milena M McLaughlin; John S Esterly; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

3.  Commentary: Back to the future with Sir Bradford Hill: statistical analysis with hospital-acquired infections.

Authors:  Michelle Shardell; Nicholas G Reich; Eli N Perencevich
Journal:  Int J Epidemiol       Date:  2013-09-14       Impact factor: 7.196

4.  Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections.

Authors:  Jill M Butterfield; Brian T Tsuji; Jack Brown; Elizabeth Dodds Ashley; Dwight Hardy; Kristen Brown; Alan Forrest; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

5.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

6.  Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.

Authors:  Sonia N Rao; Nathaniel J Rhodes; Benjamin J Lee; Marc H Scheetz; Amy P Hanson; John Segreti; Christopher W Crank; Sheila K Wang
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

7.  Development and validation of a Clostridium difficile infection risk prediction model.

Authors:  Erik R Dubberke; Yan Yan; Kimberly A Reske; Anne M Butler; Joshua Doherty; Victor Pham; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

8.  Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.

Authors:  Gregory A Eschenauer; Peggy L Carver; Shu-Wen Lin; Kenneth P Klinker; Yee-Chun Chen; Brian A Potoski; Ryan K Shields; Cornelius J Clancy; Minh-Hong Nguyen; Simon W Lam
Journal:  J Antimicrob Chemother       Date:  2012-12-04       Impact factor: 5.790

9.  Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose.

Authors:  Gregory A Eschenauer; Peggy L Carver; Twisha S Patel; Shu-Wen Lin; Kenneth P Klinker; Manjunath P Pai; Simon W Lam
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

10.  Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.

Authors:  Nathaniel J Rhodes; Joseph L Kuti; David P Nicolau; Scott Van Wart; Anthony M Nicasio; Jiajun Liu; Benjamin J Lee; Michael N Neely; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.